Published in final edited form as:

Clin Cancer Res. 2011 January 1; 17(1): 3–5. doi:10.1158/1078-0432.CCR-10-2686.

Molecular Targeting of Neural Cancer Stem Cells: TTAGGG, You're It!:

Commentary on Castelo-Branco et al

Anita B. Hjelmeland¹ and Jeremy N. Rich¹

¹Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland OH

Summary

Telomerase is an important mechanism by which cancers escape replicative senescence. In neural tumors, cancer stem cells express telomerase suggesting that this may explain their preferential tumorigenesis. Oligonucleotide telomerase targeting selectively disrupts cancer stem cell growth through the induction of differentiation, adding to the armamentarium of anti-cancer stem cell therapies.

In this issue of *Clinical Cancer Research*, Castelo-Branco and colleagues (1) report that neural cancer stem cells activate telomerase and display preferential sensitivity to a telomerase inhibitor.

Cancers are complex organ systems with multiple constituent cell types and heterogeneity within the neoplastic cellular compartment. Tumorigenic cells are often rare within cancers suggesting that not all neoplastic cells contribute to tumor maintenance. Clonal tumor cell variation derives from genetic diversity, presumably from stochastic mutational events. Additionally, many cancers display cellular hierarchies with epigenetically distinguished neoplastic cells functionally defined by their capacities to self-renew and propagate tumors phenotypically identical to the tumor from which they were derived [called cancer stem cells, tumor initiating cells, or tumor propagating cells] (2). These models of cellular heterogeneity are not mutually exclusive as many driver mutations in cancer regulate stem cell pathways. The significance of cancer stem cells is supported by their ability to resist conventional therapies and promote tumor angiogenesis and cellular dispersal (2). Core stem cell pathways – Notch, hedgehog, and wnt – are the focus of many drug development efforts with some initial promise (3). However, no single approach is likely to be universally effective due to cancer's rapid adaptability and the potential toxicity against normal stem cells (3).

Self renewal and sustained proliferation require chromosomal replication. In mitosis, cells face the challenge of incomplete replication of chromosome ends due to the biochemistry of DNA polymerases (4). Chromosome ends are protected through repetitive sequences (TTAGGG in humans) that form complex four-stranded structures (G-quadruplexes). During each round of cell division, telomere length progressively decreases unless replenished by a ribonucleoprotein enzyme complex called telomerase containing a template RNA (TERC, TELomerase RNA Component) and reverse transcriptase (TERT, TELomerase Reverse Transcriptase). Maintenance of long telomeres is critical for genomic integrity

during self-renewal in embryonic stem cells and select progenitors. The degradation of telomeres with repeated mitoses suppresses transformation as cells hit a replicative limit and undergo senescence controlled by p53 and RB pathways. Rare cells overcome the p53 and RB checkpoints but enter crisis when telomeres become critically short. To become fully transformed, a cancer cell must overcome these three barriers (p53, RB, and telomere maintenance) (5). It is not therefore surprising that mutational inactivation of p53 and RB is nearly universal in many cancers and that abnormal telomere maintenance is a common feature as well. Two predominant mechanisms for telomere regulation in cancer have been described: aberrant expression of telomerase or activation of the Alternative Lengthening of Telomeres (ALT) pathway. The activation of stem cell programs and the importance of telomerase for immortalization led to the suggestion that cancer stem cells have elevated telomerase activity which facilitates telomere maintenance (4).

In this issue of *Clinical Cancer Research*, Castelo-Branco and colleagues examine telomerase activity and telomere maintenance of neural tumor (glioma and neuroblastoma) subpopulations in comparison to normal stem cells (1). These cancers are attractive models to study tumor cell heterogeneity as studies support cellular hierarchies in each tumor type and telomere biology has already been investigated in brain cancers (6-8). The current report displays significant rigor in addressing some of the major deficits plaguing the cancer stem cell field. They avoid the use of cell lines that acquire artifactual self-renewal mechanisms due to cell culture conditions and phenotypically validate the functional characteristics of cancer stem cells.

Telomerase expression in brain tumors may have prognostic significance as elevated telomerase activity has been linked to poor patient survival. The percentage of telomerase positive brain tumors varies significantly between studies, ranging from 30 to 100% in the most malignant cancers, but consistent increases in telomerase activity have been noted with brain tumor grade (9). As telomerase activity has not been detected in normal brain, telomerase has been identified as an attractive therapeutic target for brain tumors (9-12). However, significant variability in the telomere length between brain tumor patient specimens suggests that targeting telomerase may only be beneficial against a subset of brain tumors. Indeed, targeting telomerase in glioma cells with longer telomeres does not have a significant effect until more than 30 population doublings. It should be noted however that telomerase may regulate cellular phenotypes independent from its telomere maintenance activity and subsets of cancers may depend on ALT pathways (8).

In the current report, the authors prospectively segregate tumor propagating populations using the CD15 [stage specific embryonic antigen-1 (SSEA-1), Lewis X antigen] cell surface marker and find that telomerase activity is specific to the CD15+ subpopulation in glioma patient specimens with no detectable activity in non-stem CD15- cells or normal neural stem cells¹. Their data and that from Marian et al. with CD133+ glioma cells (10) show that cancer stem cells have shortened telomeres compared to normal brain or non-stem glioma cells. As decreased telomere length characterizes glioma stem cells regardless of the marker used for isolation, cancer stem cells do not share the long telomeres characteristic of normal stem cells. These data suggest that cancer stem cells may be the rare cells which escape senescence to become immortalized (4).

The Castelo-Branco study further demonstrates that the elevated telomerase activity in glioma stem cells is due to increased hTERT mRNA expression (1), although the molecular mechanisms responsible for this transcriptional dysregulation remain unknown. Histone acetylation and methylation of CpG islands regulate TERT expression, suggesting a role for epigenetic modification which is likely different in cancer stem cells. The TERT promoter also contains binding sites for multiple transcription factors, including those known to be

involved in cancer stem cells biology. C-myc and hypoxia-inducible factor (HIF) binding elements are present in the promoter of TERT and both are critical regulators of glioma stem cells. Ets mediated TERT transcription is activated by epidermal growth factor, a core component for cancer stem cell maintenance. Thus, further studies will need to delineate the stem cell pathways mediating transcriptional elevation of TERT in cancer stem cells.

Based on this background, anti-telomerase pharmaceuticals have been developed. One of these, imetelstat (GRN163L, an oligonucleotide that directly inhibits telomerase enzymatic activity), displays efficacy against glioma cell lines and xenografts (10-12). Shortened telomeres in cancer cells and elevated telomerase activity of neural stem cells suggest a high potential therapeutic index. Glioma and neuroblastoma stem cells treated with imetelstat display attenuated cell proliferation and neurosphere formation capacity, an indicator of self-renewal (1). Telomerase targeting may critically shorten the limited telomeres of cancer stem cells triggering DNA damage responses. Subsequent cell cycle arrest may be followed by cell death (10) or differentiation (1,11; Figure 1). However, the increased DNA repair capacity and apoptotic resistance of cancer stem cells may permit long term resistance. Ultimately, lineage tracing experiments will be needed to fully examine the fate of individual cells with telomerase inhibition strategies.

Imetelstat treatment immediately after implantation of neuroblastoma stem cells improves the survival of xenograft bearing mice but treatment of established tumors did not significantly improve survival (1), a common outcome for monotherapies in many cancers. The viability of glioblastoma stem cells treated with temozolomide was further decreased by treatment with imetelstat, with minimal additional benefit of irradiation (10). Imetelstat may increase DNA damage induced by either temozolomide or irradiation to promote growth arrest (10). In conclusion, these studies strongly support potential benefits of targeting telomerase as an anti-cancer stem cell therapy in combination with conventional therapy (or other anti-cancer stem cell therapies) in advanced cancers. Imetelstat is in early clinical development and future studies may identify patients with increased sensitivity to telomerase targeting or resistance (e.g. those tumors with ALT mechanisms active).

References

1. Castelo-Branco P, Zhang C, Lipman T, et al. Neural tumor initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. *Clin Cancer Res.* This issue.
2. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. *Science.* 2009; 324:1670–1673. [PubMed: 19556499]
3. Zhou BBS, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. *Nat Rev Drug Discovery.* 2009; 8:806–823.
4. Shay JW, Wright WE. Telomeres and telomerase in normal and cancer stem cells. *FEBS Letters.* 2010; 584:3819–3825. [PubMed: 20493857]
5. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. *Nature.* 1999; 400:464–468. [PubMed: 10440377]
6. Langford LA, Piatyszek MA, Xu R, et al. Telomerase activity in human brain tumours. *Lancet.* 1995; 346:1267–1268. [PubMed: 7475720]
7. Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. *Cancer Res.* 1998; 58:2117–2125. [PubMed: 9605755]
8. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. *Lancet.* 2003; 361:836–838. [PubMed: 12642053]
9. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant glioma. *Oncogene.* 2002; 21:656–663. [PubMed: 11850793]

10. Marian CO, Cho SK, Mcellin BM, et al. The Telomerase antagonist, Imetelstat, efficiently targets tumor-initiating cells leading to decreased proliferation and tumor growth. *Clinical Cancer Research*. 2010; 16:154–163. [PubMed: 20048334]
11. Ozawa T, Gryaznov SM, Hu LJ, et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. *Neuro Oncol*. 2004; 6:218–226. [PubMed: 15279714]
12. Hashizume R, Ozawa T, Gryaznov SM, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. *Neuro Oncol*. 2008; 10:112–120. [PubMed: 18287341]

Figure 1. Anti-telomerase based neural stem cell therapies

Normal neural stem cells display longer telomeres than cancer stem cells which also display elevated levels of hTERT. Cancer stem cells display preferential sensitivity to the telomerase inhibitor imetelstat (GRN163L), an oligonucleotide that directly inhibits telomerase enzymatic activity. Glioma and neuroblastoma stem cells treated with imetelstat have attenuated cell growth associated with decreased neurosphere formation capacity, an indicator of self-renewal. Decreased self-renewal with telomerase inhibition may also be due to increased differentiation or cell death.